)*( Bend over rover. OMG what a filthy mutt this thing is.
This is just like when you think you have a beautiful home and then your neighbor's filthy mutt runs over, hunches up a straining squat and deposits a huge, disgusting, log-like pile of steamy, worm-infested used dog chow directly outside your front door. Bleeeeeeackkkkk!!!!! Back on topic now.
IMGN is stuck in a range where it's a buy below $15 and a sell near $17 until something happens, positive or negative.
I am not overly excited about Roche's efforts to market/sell Kadcyla so far. I think their efforts/resources are less than we had hoped for. Until they expand into new markets and gain approval for earlier use, sales growth will likely remain limited.
We need progress in sales, clinical development and licensing to avoid new, additional dilution. Continued insider sales do not help investor confidence! At some point, a large shareholder is going to say stop the madness and either get someone new in here to run the business, or sell. It's time (long overdue) for the stock to perform, or at least stop underperforming.